メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
岡山大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
設備
活動
プレス/メディア
受賞
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
西村 慎吾
助教
,
岡山大学病院
h-index
110
被引用数
6
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2012
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(37)
類似のプロファイル
(6)
フィンガープリント
Shingo Nishimuraが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Transitional Cell Carcinoma
87%
Computer Assisted Tomography
66%
Cystectomy
50%
Cryoablation
50%
Pembrolizumab
50%
Kidney Function
50%
Kidney Autotransplantation
50%
Metastatic Carcinoma
41%
Ureter
35%
Neoplasm
34%
Bladder Tumor
34%
Urine Cytology
31%
Transurethral Resection
31%
Ureteroscopy
30%
Upper Urinary Tract
28%
Urinary Diversion
25%
Alpha-Linolenic Acid
25%
Gastrointestinal Cancer
25%
Ureter Injury
25%
Kidney Graft
25%
Fumarate Hydratase
25%
Urethra Tumor
25%
Partial Nephrectomy
25%
Emphysematous Pyelonephritis
25%
Diagnosis
25%
Extracorporeal
25%
Blood Group Incompatibility
25%
BK Virus
25%
Ureteroureterostomy
25%
Von Hippel-Lindau Disease
25%
Ureter Tumor
25%
Nivolumab
25%
Antithrombotic Therapy
25%
Urothelial Cancer
25%
Ipilimumab
25%
Diabetes Mellitus
25%
Nephropathy
25%
Kidney Allograft
25%
Survival Time
24%
Recurrent Disease
23%
Overall Survival
22%
Biopsy
20%
Cancer Specific Survival
20%
Cancer Cell
20%
Operation Duration
18%
Robot-Assisted Surgery
16%
Ureteropelvic Junction Obstruction
16%
Medicine
16%
Kidney Transplantation
15%
Keyphrases
Estramustine
25%
Transurethral Resection
25%
Unfit Patients
25%
Robotic-assisted
25%
Cyclophosphamide
25%
Renal Cell Carcinoma
25%
Baseline Tumor Size
25%
BK Virus Nephropathy
25%
Fumarate Hydratase
25%
Fumarate Hydratase-deficient Renal Cell Carcinoma
25%
Tacrolimus
25%
Urethral Tumor
25%
Antithrombotic Therapy
25%
Castration-resistant Prostate Cancer
25%
Polycystic
25%
Cefditoren pivoxil
25%
Deceased Donor Kidney Transplantation
25%
COVID-19 Treatment
25%
SARS-CoV-2 PCR
25%
Vonoprazan
25%
Ureteral Calculi
25%
Ureteroureterostomy
25%
Low-dose Rituximab
25%
Slow Graft Function
25%
Ureteroscopic Lithotripsy
25%
Blood Concentration
25%
Inflammatory Syndrome
25%
Urinary Bladder Cancer
25%
Bladder Tuberculosis
25%
Rabeprazole
25%
Gene Polymorphism
25%
Ipilimumab
25%
Kidney Donation
25%
Nivolumab
25%
Cytochrome P450 Enzymes
25%
Renal Transplant Recipients
25%
Bladder Tumor
25%
Muscular Development
25%
Trans Men
25%
Body Composition Changes
25%
Tacrolimus Trough Level
15%
Ureterorenoscopy
15%
Ureteral Injury
12%
Pyelectasis
12%
Cervical Cancer Metastasis
12%
4-cycle
12%
Relative Renal Function
12%
Robot-assisted Partial Nephrectomy
12%
Descending Colon Cancer
12%
Large Baseline
11%
Pharmacology, Toxicology and Pharmaceutical Science
Pembrolizumab
75%
Transitional Cell Carcinoma
75%
Malignant Neoplasm
26%
Tacrolimus
25%
Rituximab
25%
Infection
25%
Renal Cell Carcinoma
25%
Antimicrobial Therapy
25%
First-Line Chemotherapy
25%
Proton Pump Inhibitor
25%
Cefditoren Pivoxil
25%
Neoplasm
25%
Gemcitabine
25%
Estramustine
25%
Vonoprazan
25%
Cisplatin
25%
Rabeprazole
25%
Paclitaxel
25%
Cytochrome P450
25%
Antacid Agent
25%
Endocrine Therapy
25%
Progression Free Survival
20%
Immune Checkpoint Inhibitor
19%
Overall Survival
17%
Histamine H2 Receptor Antagonist
17%
Antiinfective Agent
16%
Kidney Metastasis
16%
Survival Time
14%
Urinary Tract Infection
12%
Recurrent Disease
11%
Primary Tumor
11%
Trough Level
9%
Combination Therapy
8%
Clinical Trial
8%
Disease
8%
Pyelonephritis
8%
Tumor Microenvironment
8%
Metastasis
8%
Surgical Infection
8%
Creatinine
8%
Cancer Specific Survival
7%
CYP2C19
6%
Triacylglycerol
6%
Polycythemia vera
6%
Dyslipidemia
6%
Uric Acid
6%
Side Effect
6%
Adverse Event
5%
